Results 231 to 240 of about 38,538 (308)
Targeting Tumor Stroma: Current Challenges and Future Directions
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang +7 more
wiley +1 more source
Structural stability of symmetric bispecific antibodies: a case study showing potential compromise near linker regions. [PDF]
Ingavat N +13 more
europepmc +1 more source
Aptamer‐functionalized nanocarriers represent a versatile platform for targeted therapy in bone and joint diseases. This review presents five complementary design strategies: free aptamers for soluble targets, bispecific multivalent constructs for enhanced avidity, nanoparticle‐conjugated aptamers for selective tissue accumulation, aptamer‐based ...
Hamdi Al‐Azzani +5 more
wiley +1 more source
Recurrent cytokine release syndrome in patients receiving bispecific antibody therapy for multiple myeloma: a case series. [PDF]
Della Pepa R +7 more
europepmc +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
The making of multispecific immunoglobulins - a clinical perspective. [PDF]
Brinkmann U, Kontermann RE.
europepmc +1 more source
RUNX‐dependent transcriptional control of SOS1 reinforces HER2–RAS signaling and may attenuate responses to HER2‐targeted therapies in HER2‐positive gastric cancer. ABSTRACT HER2‐positive gastric cancer represents a distinct molecular subtype characterized by chromosomal instability, variable HER2 amplification, and substantial intratumoral ...
Tatsuya Masuda +3 more
wiley +1 more source
Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches. [PDF]
Godugu D +5 more
europepmc +1 more source
Elranatamab: Mechanism of Action, Clinical, and Translational Science
ABSTRACT Elranatamab (ELREXFIO) is a humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM). Elranatamab engages CD3 on T cells and B‐cell maturation antigen (BCMA) on myeloma cells to induce T cell–mediated myeloma cell cytolysis.
Mohamed Elmeliegy +10 more
wiley +1 more source

